Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, has announced it will release its fourth quarter and full year 2024 financial results on Wednesday, February 19, 2025, before U.S. markets open. The company's management will host a conference call and webcast at 8:30 am ET on the same day to discuss financial results and provide a business update.
A live webcast will be accessible to investors and the public, with a 30-day replay available on the company's investor relations website.
Krystal Biotech (NASDAQ: KRYS), un'azienda biotecnologica in fase commerciale, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 mercoledì 19 febbraio 2025, prima dell'apertura dei mercati statunitensi. La direzione dell'azienda ospiterà una conferenza telefonica e un webcast alle 8:30 AM ET nello stesso giorno per discutere i risultati finanziari e fornire un aggiornamento sull'attività.
Un webcast dal vivo sarà accessibile a investitori e pubblico, con una riproduzione disponibile per 30 giorni sul sito web delle relazioni con gli investitori dell'azienda.
Krystal Biotech (NASDAQ: KRYS), una empresa de biotecnología en etapa comercial, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el miércoles 19 de febrero de 2025, antes de la apertura de los mercados en EE.UU. La dirección de la empresa llevará a cabo una conferencia telefónica y un webcast a las 8:30 AM ET el mismo día para discutir los resultados financieros y proporcionar una actualización empresarial.
Se podrá acceder a un webcast en vivo para inversores y el público, con una repetición disponible durante 30 días en el sitio web de relaciones con inversores de la empresa.
Krystal Biotech (NASDAQ: KRYS), 상업 단계의 생명공학 회사,가 2024년 4분기 및 전체 연도 재무 결과를 2025년 2월 19일 수요일, 미국 시장 개장 전에 발표할 것이라고 발표했습니다. 회사 경영진은 같은 날 오전 8시 30분 ET에 재무결과를 논의하고 사업 업데이트를 제공하기 위해 컨퍼런스 콜 및 웹캐스트를 개최할 것입니다.
라이브 웹캐스트는 투자자 및 대중이 접근할 수 있으며, 회사의 투자자 관계 웹사이트에서 30일 동안 재생할 수 있습니다.
Krystal Biotech (NASDAQ: KRYS), une entreprise de biotechnologie en phase commerciale, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année entière 2024 le mercredi 19 février 2025, avant l'ouverture des marchés américains. La direction de l'entreprise tiendra une conférence téléphonique et un webinaire le même jour à 8h30 ET pour discuter des résultats financiers et fournir une mise à jour sur l'activité.
Un webinaire en direct sera accessible aux investisseurs et au public, avec une rediffusion disponible pendant 30 jours sur le site web des relations avec les investisseurs de l'entreprise.
Krystal Biotech (NASDAQ: KRYS), ein biotechnologisches Unternehmen in der Kommerzialisierungsphase, hat angekündigt, dass es seine finanziellen Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 am Mittwoch, den 19. Februar 2025, vor der Eröffnung der US-Märkte veröffentlichen wird. Das Management des Unternehmens wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die finanziellen Ergebnisse zu besprechen und ein Update zum Geschäft zu geben.
Ein Live-Webcast wird für Investoren und die Öffentlichkeit zugänglich sein, mit einer 30-tägigen Wiederholung auf der Website für Investorenbeziehungen des Unternehmens.
- None.
- None.
PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its fourth quarter and full year 2024 financial results on Wednesday, February 19, 2025, prior to the open of U.S. markets.
The Company’s management will also host a conference call and webcast at 8:30 am ET on Wednesday, February 19, 2025, to discuss the financial results and provide a business update.
Investors and the general public can access the live webcast at: https://www.webcaster4.com/Webcast/Page/3018/51976.
For those unable to listen to the live webcast, a replay will be available for 30 days on the Investors section of the Company’s website at www.krystalbio.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
FAQ
When will Krystal Biotech (KRYS) release Q4 and full year 2024 earnings?
What time is Krystal Biotech's (KRYS) Q4 2024 earnings call?
How can investors access Krystal Biotech's (KRYS) Q4 2024 earnings webcast?
How long will Krystal Biotech's (KRYS) Q4 2024 earnings webcast replay be available?
